Alliance scholar awardS

Each year, the Alliance for Clinical Trials in Oncology Foundation invites applications for the Alliance Scholar Awards.

Alliance Scholar Award applicants are oncology junior faculty at Alliance institutions within five (5) years of training (rank below Associate Professor), who have completed training in an oncology clinical specialty (e.g., medical, surgical, radiation, gynecologic, etc.). Additionally, applicant proposals are nominated by an Alliance Scientific Committee Chair and are closely tied to the research agenda of the Alliance. Potential applicants must work with the relevant Alliance Scientific Committee Chair prior to submission of an application to ensure endorsement of the relevant Alliance Scientific Committee and include a letter of support from the relevant Alliance Scientific Committee Chair with application materials. Projects supported by other non-institutional funds are not eligible.

Alliance Scholar Award recipients will receive a two-year, non-renewable cancer research grant of $40,000 direct costs per year for two years. An independent scientific review committee, convened by the Alliance for Clinical Trials in Oncology Foundation, will review the endorsed applications. Successful applicants are announced during the Plenary Session at the Alliance Fall Group Meeting usually held in November of each year. Funding usually begins in January of the following year.

Application requirements can be found on our online application center portal. A CTEP-IAM username and password are needed to access the site. If you do not have a CTEP-IAM username and password, information on how to obtain one can be found at the bottom of the log-in screen.

Questions: For more information, contact Kaitlyn Kamb by e-mail at Awards@AllianceNCTN.org.


Award Recipients

2021
Xiao X. Wei, MD, MAS
- Instructor of Medicine, Harvard Medical School
Dr. Emil "Tom" Frei III ASA Project: "Impact of Immunotherapy Discontinuation on Health Economics in Patients with Advanced Urothelial Carcinoma in a Non-Inferiority Phase 3 Trial"
 
Neha Mehta-Shah, MD, MSCI
- Assistant Professor of Medicine, Washington University School of Medicine
ASA Project: "Evaluating Minimal Residual Disease in Peripheral T-cell Lymphomas Being Treated for Curative Intent in A051902"